Core Insights - CERo Therapeutics Holdings, Inc. has appointed Eric Francois to its Board of Directors, which is expected to enhance the company's strategic direction and operational capabilities [1][2]. Company Overview - CERo is an innovative cellular immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [3]. - The company’s proprietary approach integrates both innate and adaptive immunity to create a more effective therapeutic construct for tumor targeting [3]. Leadership and Expertise - Eric Francois brings over 25 years of experience in the life sciences sector, including significant roles in financial advisory and capital raising, having raised over $300 million during his tenure as CFO of SCYNEXIS [2]. - His expertise in mergers and acquisitions, along with business development, is anticipated to be a valuable asset for CERo at this stage of its growth [2]. Product Development - CERo has initiated clinical trials for its lead product candidate, CER-1236, targeting hematologic malignancies, showcasing its commitment to advancing innovative cancer therapies [3]. - The company’s unique Chimeric Engulfment Receptor T cells (CER-T) are designed to utilize phagocytic activity to destroy cancer cells, potentially offering advantages over existing CAR-T therapies [3].

Core Insights - CERo Therapeutics Holdings, Inc. is presenting data from its Phase 1 clinical trial, CERTAIN-T, for its lead compound CER-1236, which shows a positive safety profile and significant in vivo cell expansion [1][2] - The trial includes patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), demonstrating promising results such as transfusion independence in an index patient [1][3] Company Overview - CERo is an innovative cellular immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [5] - The company’s approach integrates innate and adaptive immunity to enhance tumor targeting, utilizing a novel platform referred to as Chimeric Engulfment Receptor T cells (CER-T) [5][6] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML or newly diagnosed TP53 mutated AML [3] - The trial has been amended to include transfusion-dependent myelodysplastic syndromes (TD-MDS) and high-risk MDS (HR-MDS) based on emerging safety data [3][4] Safety and Efficacy Observations - Early clinical findings indicate a favorable safety and tolerability profile for CER-1236, with no dose-limiting toxicities or observed cytokine release syndrome (CRS) in the initial patients [2][4] - The trial's primary outcome measures include the incidence of adverse events, dose-limiting toxicities, and overall response rates [3]

Core Insights - CERo Therapeutics Holdings, Inc. has made significant progress in its CertainT-1 trial for acute myeloid leukemia (AML), completing the dose-limiting toxicity (DLT) observation period for the first cohort and administering a higher dose of CER-1236 to the first patient in the second cohort [1][3] Group 1: Trial Progress - The first patient in the second cohort received a dose of 4e6 cells/kg of CER-1236, which is four times higher than the 1e6 cells/kg administered to the first cohort [1] - An additional dose was provided to a second patient in the first cohort, who remains on study, indicating ongoing enrollment and dosing in the Phase 1 clinical trial [3] Group 2: Study Design and Objectives - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML, those in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML [2] - Primary outcome measures include the incidence of adverse events (AEs), serious adverse events (SAEs), dose-limited toxicities, overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD) [2] Group 3: Company Overview - CERo Therapeutics is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that integrates innate and adaptive immunity [4] - The company’s novel cellular immunotherapy platform aims to redirect patient-derived T cells toward tumor cells, employing phagocytic activity to destroy cancer cells, which may offer advantages over currently approved CAR-T therapies [4]

Core Insights - CERo Therapeutics Holdings, Inc. has initiated the second cohort of its Phase 1 clinical trial for CER-1236, targeting patients with acute myeloid leukemia (AML) [1][2] - The first patient in this cohort received an initial dose of CER-1236 at twice the initial dose given to patients in the first cohort, with a follow-up dose 48 hours later [1][2] - The trial aims to evaluate the safety and preliminary efficacy of CER-1236 in various AML patient populations, including those who are relapsed/refractory or newly diagnosed with TP53 mutated MDS/AML [2] Clinical Trial Details - The Phase 1/1b study is designed to assess safety and preliminary efficacy, with primary outcome measures including adverse events, dose-limiting toxicities, and overall response rates [2] - The study consists of a dose escalation phase to determine the highest tolerated dose, followed by an expansion phase to further evaluate safety and efficacy [2] - Secondary outcome measures include pharmacokinetics [2] Company Strategy and Future Outlook - The CEO of CERo expressed optimism regarding the trial's progress, highlighting the safety data and cell expansion observed so far [3] - The company is focused on the development of CER-1236 and is considering options for listing on a public exchange while continuing the clinical study [3] - CERo's innovative approach integrates innate and adaptive immunity in T cell engineering, potentially offering advantages over existing CAR-T therapies [4]

Core Insights - CERo Therapeutics Holdings, Inc. is presenting data on its lead compound CER-1236 at the Society for Immunotherapy of Cancer (SITC) conference from November 5-9, 2025 [1] - The poster presentation highlights preclinical data demonstrating the sustained effector function and resistance to exhaustion of CER-1236, showing durability of activity compared to traditional stimulation methods [2] - The CEO of CERo expressed confidence in the data supporting the ongoing Phase 1 trial, which aims to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, integrating both innate and adaptive immunity in its approach [4] - The company’s proprietary platform, which includes Chimeric Engulfment Receptor T cells (CER-T), aims to enhance tumor targeting capabilities compared to existing CAR-T therapies [4] - CERo has initiated clinical trials for CER-1236 specifically targeting hematologic malignancies [4]

Core Insights - CERo Therapeutics Holdings, Inc. continues to trade under the ticker symbol CERO on the OTC Markets, with no action required from investors [1] - The company is exploring options for an up-list to enhance liquidity and investor accessibility [1] - CEO Chris Ehrlich emphasized the company's commitment to maximizing shareholder value and advancing its clinical trials, particularly for CER-1236 in AML [2] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, integrating both innate and adaptive immunity [3] - The company's proprietary platform aims to redirect patient-derived T cells towards tumor cells using both adaptive and innate mechanisms, creating Chimeric Engulfment Receptor T cells (CER-T) [3] - CERo believes that CER-T cells may provide advantages over existing CAR-T therapies and could be effective for both hematologic malignancies and solid tumors [3] - Clinical trials for CER-1236, the lead product candidate, have been initiated for hematologic malignancies [3]

Core Points - CERo Therapeutics Holdings, Inc. will have its shares suspended from trading on Nasdaq starting October 31, 2025, following a determination by the Nasdaq Hearings Panel to deny the company's request for continued listing [1] - The company plans to appeal the Panel's decision and is seeking to trade its shares on the OTC Markets while continuing its clinical operations [1][5] Financial Compliance - CERo has struggled to comply with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million [2] - In April 2025, the company believed it had regained compliance after a financing round that included the issuance of Series D Convertible Preferred Stock valued at $5 million [2] - However, due to difficulties in valuing Marketable Securities, the company sold them at a substantial discount, leading to a determination of non-compliance with the Equity Rule [3][4] Panel Decision - The Nasdaq Panel's decision was based on a retroactive assessment of non-compliance as of April 22, 2025, disregarding the company's plans for future compliance [4] - The company has executed parts of its compliance plan, including receiving approximately $2.25 million from the sale of Series E Convertible Preferred Stock and subscriptions for an additional $4.75 million [4] Future Plans - CERo has submitted a request for review of the Panel's decision and is exploring trading on the OTC Markets, although this market is less liquid than Nasdaq [5] - The company intends to continue its clinical trials, specifically for its lead product candidate, CER-1236, which has shown promising early-stage results in patients with AML [6][7] - CERo is reviewing its cash resources and potential financing alternatives to support ongoing operations [7] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a unique approach that combines innate and adaptive immunity [8] - The company's proprietary technology aims to enhance tumor targeting through Chimeric Engulfment Receptor T cells (CER-T), which may offer advantages over existing CAR-T therapies [8]

Core Insights - CERo Therapeutics Holdings, Inc. has completed the first tranche of a $7 million financing, amounting to approximately $2.3 million, to extend its cash runway and maintain compliance with Nasdaq listing requirements [2][4] - The company is advancing its Phase 1 clinical trial for CER-1236, with a third infusion administered to a patient to gather more safety and dosing information [1][3] - The ongoing clinical trial aims to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia, focusing on various patient conditions [3] Financing and Compliance - The financing is expected to support the company's efforts to maintain Nasdaq compliance and extend its operational cash runway [2][4] - The successful completion of the first tranche reinforces the company's capital structure and positions it to begin the second cohort of the clinical trial once regulatory approvals are obtained [4] Clinical Trial Details - The Phase 1/1b study is designed to assess the safety and efficacy of CER-1236 in patients with acute myeloid leukemia, including those who are relapsed/refractory or newly diagnosed with TP53 mutated MDS/AML [3] - Primary outcome measures include the incidence of adverse events, dose-limited toxicities, and overall response rates, while secondary measures focus on pharmacokinetics [3] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a unique approach that combines innate and adaptive immunity [5] - The company's proprietary technology aims to enhance tumor targeting through Chimeric Engulfment Receptor T cells (CER-T), potentially offering advantages over existing CAR-T therapies [5]

Core Insights - CERo Therapeutics Holdings, Inc. is participating in a stem cell therapy panel at the Maxim Growth Summit on October 22-23, 2025, in New York City [1][2] - The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director at Maxim Group [2] - Chris Ehrlich, CEO of CERo, will be available for one-on-one meetings during the conference [3] Company Overview - CERo is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment [4] - The company’s proprietary T cell engineering approach integrates characteristics of both innate and adaptive immunity, aiming to optimize cancer therapy [4] - CERo's Chimeric Engulfment Receptor T cells (CER-T) are designed to redirect patient-derived T cells to eliminate tumors using phagocytic mechanisms, potentially allowing broader therapeutic applications than current CAR-T therapies [4] - Clinical trials for CERo's lead product candidate, CER-1236, targeting hematological malignancies have commenced [4]

Core Insights - CERo Therapeutics has completed the first cohort of its Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML), with no dose-limiting toxicities observed and cell expansion consistent with preclinical expectations [1][2][4] - The Dose Escalation Safety Committee has approved the initiation of the second cohort, where three new patients will receive an increased starting dosage [2][4] - The company is not currently seeking partnerships or acquisitions, focusing instead on advancing its clinical trial [5] Company Overview - CERo Therapeutics is an innovative immunotherapy company developing next-generation engineered T cell therapeutics for cancer treatment, integrating innate and adaptive immunity [6] - The company’s lead product candidate, CER-1236, is designed to target both hematologic malignancies and solid tumors, utilizing a novel cellular immunotherapy platform [6][7] Clinical Trial Details - The Phase 1/1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory AML or newly diagnosed patients with TP53 mutated MDS/AML [4] - Primary outcome measures include the incidence of adverse events, dose-limiting toxicities, and overall response rates, while secondary measures focus on pharmacokinetics [4]